Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • AChE
    (1)
  • MAO
    (1)
  • Others
    (16)
Filter
Search Result
Results for "

target/AChE/1

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    16
    TargetMol | Activity
  • Recombinant Protein
    1
    TargetMol | inventory
AChE/BChE/MAO-B-IN-1
T608912416910-82-0
AChE BChE MAO-B-IN-1 is a reversible, non-time-dependent inhibitor of AChE, BChE, and MAO-B that crosses the blood-brain barrier, exhibiting inhibitory effects on hAChE, hBChE, and hMAO-B with IC50s of 7.31, 0.56, and 26.1 μM, respectively. [AChE BChE MAO-B-IN-1] had a neuroprotective effect and was not significantly cytotoxic.
  • $98
In Stock
Size
QTY
Target 1
T9467 In house
Target 1 has a wide range of applications in life science related research.
    Inquiry
    AChE/MAO-IN-1
    T72892
    AChE/MAO-IN-1 is a potent inhibitor of human acetylcholinesterase (AChE), monoamine oxidase A (MAO-A), and monoamine oxidase B (MAO-B), demonstrating inhibitory concentrations (IC50) of 0.0248 μM, 0.0409 μM, and 0.1108 μM against AChE, MAO-A, and MAO-B, respectively.
    • $1,520
    6-8 weeks
    Size
    QTY
    Dual AChE-MAO B-IN-1
    T62172
    Dual AChE-MAO B-IN-1 (compound 15) is a safe, metabolically stable neuroprotective agent. This potent, orally active, CNS-permeable inhibitor demonstrates IC50 values of 550 nM for human AChE and 8.2 nM for MAO-B, indicating low in vitro activity against these enzymes.
    • $1,520
    10-14 weeks
    Size
    QTY
    AChE/BChE-IN-1
    T64156
    AChE BChE-IN-1 is a potent dual inhibitor of acetylcholinesterase and butyrylcholinesterase with blood-brain barrier permeability, exhibiting IC50 values of 1.06 nM for hAChE and 7.3 nM for hBChE, and showing antioxidant effects. AChE BChE-IN-1 can be used in Alzheimer's disease research.
    • $1,520
    10-14 weeks
    Size
    QTY
    AChE/BChE/BACE-1-IN-2
    T606911877000-20-8
    AChE BChE BACE-1-IN-2 (Compound 4o) is an orally active AChE, BACE-1, and BChE inhibitor with IC50 values of 0.069, 0.097, and 0.127 μM against hAChE, hBACE-1, and hBChE, respectively. It exhibits remarkable antioxidant potential, considerable binding capability towards PAS-AChE, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress with excellent brain permeation [1].
    • $1,520
    6-8 weeks
    Size
    QTY
    AChE/PDE4-IN-1
    T61620
    AChE PDE4-IN-1 (compound 12c) is a highly effective and specific dual inhibitor of PDE4 and AChE, with IC50 values of 0.28 μM for AChE and 1.88 μM for PDE4D. This compound shows notable potential in reducing neuroinflammation associated with Alzheimer's disease research [1].
    • $1,520
    10-14 weeks
    Size
    QTY
    AChE/BACE1/GSK3β-IN-1
    T62719
    AChE BACE1 GSK3β-IN-1 is an orally active, blood-brain barrier-permeable, moderately bioavailable triple inhibitor of AChE, BACE1, and GSK3β, utilized for Alzheimer's disease (AD) research.
    • $1,520
    10-14 weeks
    Size
    QTY
    AChE/HDAC-IN-1
    T631422414053-06-6
    COX-2-IN-23 (compound A10) is a potent inhibitor of AChE (IC50: 0.12 nM) and HDAC (IC50: 0.23 nM), exhibiting antioxidant and metal-chelating properties, which can be used to study Alzheimer's disease.
    • $1,520
    6-8 weeks
    Size
    QTY
    AChE/BChE/BACE-1-IN-1
    T612061321361-13-0
    AChE BChE BACE-1-IN-1 (Compound 4k) is an orally active inhibitor that targets acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and β-site amyloid precursor protein cleaving enzyme 1 (BACE-1), with IC50 values of 0.058 μM, 0.082 μM, and 0.115 μM against hAChE, hBChE, and hBACE-1, respectively. It exhibits significant binding affinity with PAS-AChE, excellent blood-brain barrier permeability, potential disassembly of amyloid-beta (Aβ) aggregates, neuroprotective properties against Aβ-induced stress, and remarkable antioxidant capabilities [1].
    • $1,520
    6-8 weeks
    Size
    QTY
    AChE/GSK-3β-IN-1
    T641432412364-73-7
    AChE/GSK-3β-IN-1 is a potent dual AChE/GSK-3β inhibitor that crosses the blood-brain barrier and acts on hAChE (IC50: 1.2 nM), hBChE (IC50: 149.8 nM) and hGSK-3β (IC50: 22.4 nM). AChE/GSK-3β-IN-1 is able to occupy the ATP binding site of DYRK1A. aChE/GSK-3β-IN-1 exhibits high kinase selectivity for the CMGC kinase family. aChE/GSK-3β-IN-1 inhibits ROS expression and reduces oxidative stress. aChE/GSK-3β-IN-1 can be used to study Alzheimer's disease.
    • $1,520
    10-14 weeks
    Size
    QTY
    AChE/hCA I/II-IN-1
    T604502049681-10-7
    AChE hCA I II-IN-1 (Compound 6) is a potent AChE Hca inhibitor with IC50 values of 22.21, 60.79, and 66.64 nM for AChE, Hca Ⅰ, and Hca Ⅱ. AChE hCA I II-IN-1 can be used in glaucoma, Alzheimer's disease, and diabetes research[1].
    • $1,520
    6-8 weeks
    Size
    QTY
    sEH/AChE-IN-1
    T641812490589-08-5
    sEH AChE-IN-1 (Compound 12a) is a dual inhibitor of soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE) with potential research applications in Alzheimer's disease (AD) due to its cumulative effect against neuroinflammation and memory impairment.
    • $1,520
    6-8 weeks
    Size
    QTY
    AChE/Aβ-IN-1
    T79569
    AChE Aβ-IN-1 (compound 32) is a potent, orally active acetylcholinesterase (AChE) inhibitor with an IC50 of 86 nM and an NMDA receptor antagonist targeting the GluN1-1b GluN2B subunit combination with an IC50 of 3.876 μM. It also impedes Aβ aggregation, exhibits favorable blood-brain barrier permeability, offers neuroprotection, and enhances cognitive and spatial memory in rat models [1].
    • Inquiry Price
    Size
    QTY
    AChE/Nrf2 modulator 1
    T724172417117-84-9
    AChE/Nrf2 modulator 1, an orally active compound, serves as a modulator of acetylcholinesterase (AChE) and nuclear factor erythroid 2-related factor 2 (Nrf2). It exhibits Nrf2 inductive activity alongside inhibitory effects on eeAChE and hAChE, demonstrating IC 50 values of 0.07 μM and 0.38 μM, respectively. This compound is applicable in Alzheimer's disease research.
    • $1,520
    6-8 weeks
    Size
    QTY
    AChE/BuChE-IN-1
    T7276384212-49-7
    AChE/BuChE-IN-1, a selective butyrylcholinesterase (BuChE) inhibitor derived from chrysin, exhibits a potent efficacy with an IC50 of 0.48 μM against BuChE and a lesser inhibitory effect on acetylcholinesterase (AChE) with an IC50 of 7.16 μM. It demonstrates significant hydroxyl radical (·OH) scavenging activity, achieving an IC50 of 0.1674 μM, and effectively inhibits reactive oxygen species (ROS) and Aβ 1-42 aggregation, including self-aggregation, copper (Cu 2+)-induced, and AChE-induced aggregation. Characterized by high blood-brain barrier (BBB) permeability, bioavailability, and low cellular toxicity, AChE/BuChE-IN-1 holds promising potential for Alzheimer's disease (AD) research.
    • $1,520
    6-8 weeks
    Size
    QTY